Literature DB >> 24064216

Mutations in intracellular loops 1 and 3 lead to misfolding of human P-glycoprotein (ABCB1) that can be rescued by cyclosporine A, which reduces its association with chaperone Hsp70.

Khyati Kapoor1, Jaya Bhatnagar, Eduardo E Chufan, Suresh V Ambudkar.   

Abstract

P-glycoprotein (P-gp) is an ATP binding cassette transporter that effluxes a variety of structurally diverse compounds including anticancer drugs. Computational models of human P-gp in the apo- and nucleotide-bound conformation show that the adenine group of ATP forms hydrogen bonds with the conserved Asp-164 and Asp-805 in intracellular loops 1 and 3, respectively, which are located at the interface between the nucleotide binding domains and transmembrane domains. We investigated the role of Asp-164 and Asp-805 residues by substituting them with cysteine in a cysteine-less background. It was observed that the D164C/D805C mutant, when expressed in HeLa cells, led to misprocessing of P-gp, which thus failed to transport the drug substrates. The misfolded protein could be rescued to the cell surface by growing the cells at a lower temperature (27 °C) or by treatment with substrates (cyclosporine A, FK506), modulators (tariquidar), or small corrector molecules. We also show that short term (4-6 h) treatment with 15 μM cyclosporine A or FK506 rescues the pre-formed immature protein trapped in the endoplasmic reticulum in an immunophilin-independent pathway. The intracellularly trapped misprocessed protein associates more with chaperone Hsp70, and the treatment with cyclosporine A reduces the association of mutant P-gp, thus allowing it to be trafficked to the cell surface. The function of rescued cell surface mutant P-gp is similar to that of wild-type protein. These data demonstrate that the Asp-164 and Asp-805 residues are not important for ATP binding, as proposed earlier, but are critical for proper folding and maturation of a functional transporter.

Entities:  

Keywords:  ABC Transporter; Chemical Chaperones; Drug Resistance; Molecular Chaperone; Multidrug Transporters; P-glycoprotein; Protein Misfolding

Mesh:

Substances:

Year:  2013        PMID: 24064216      PMCID: PMC3820894          DOI: 10.1074/jbc.M113.498980

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface.

Authors:  Csilla Ozvegy-Laczka; György Várady; Gabriella Köblös; Olga Ujhelly; Judit Cervenak; John D Schuetz; Brian P Sorrentino; Gerrit-Jan Koomen; András Váradi; Katalin Német; Balázs Sarkadi
Journal:  J Biol Chem       Date:  2004-11-22       Impact factor: 5.157

2.  Structure of a bacterial multidrug ABC transporter.

Authors:  Roger J P Dawson; Kaspar P Locher
Journal:  Nature       Date:  2006-08-30       Impact factor: 49.962

3.  Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators.

Authors:  T W Loo; D M Clarke
Journal:  J Biol Chem       Date:  1997-01-10       Impact factor: 5.157

4.  P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity.

Authors:  E B Mechetner; B Schott; B S Morse; W D Stein; T Druley; K A Davis; T Tsuruo; I B Roninson
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

5.  Folding of CFTR is predominantly cotranslational.

Authors:  Bertrand Kleizen; Thijs van Vlijmen; Hugo R de Jonge; Ineke Braakman
Journal:  Mol Cell       Date:  2005-10-28       Impact factor: 17.970

6.  Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay.

Authors:  F Tiberghien; F Loor
Journal:  Anticancer Drugs       Date:  1996-07       Impact factor: 2.248

7.  Impact of the deltaF508 mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure.

Authors:  Hal A Lewis; Xun Zhao; Chi Wang; J Michael Sauder; Isabelle Rooney; Brian W Noland; Don Lorimer; Margaret C Kearins; Kris Conners; Brad Condon; Peter C Maloney; William B Guggino; John F Hunt; Spencer Emtage
Journal:  J Biol Chem       Date:  2004-11-03       Impact factor: 5.157

8.  Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state.

Authors:  M Ramachandra; S V Ambudkar; D Chen; C A Hrycyna; S Dey; M M Gottesman; I Pastan
Journal:  Biochemistry       Date:  1998-04-07       Impact factor: 3.162

9.  Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells.

Authors:  S V Ambudkar
Journal:  Methods Enzymol       Date:  1998       Impact factor: 1.600

Review 10.  Rescue of folding defects in ABC transporters using pharmacological chaperones.

Authors:  Tip W Loo; M Claire Bartlett; David M Clarke
Journal:  J Bioenerg Biomembr       Date:  2005-12       Impact factor: 3.853

View more
  13 in total

1.  Evidence for the Interaction of A3 Adenosine Receptor Agonists at the Drug-Binding Site(s) of Human P-glycoprotein (ABCB1).

Authors:  Biebele Abel; Dilip K Tosh; Stewart R Durell; Megumi Murakami; Shahrooz Vahedi; Kenneth A Jacobson; Suresh V Ambudkar
Journal:  Mol Pharmacol       Date:  2019-05-24       Impact factor: 4.436

2.  Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL.

Authors:  Paloma S Souza; James P Madigan; Jean-Pierre Gillet; Khyati Kapoor; Suresh V Ambudkar; Raquel C Maia; Michael M Gottesman; King Leung Fung
Journal:  Exp Cell Res       Date:  2015-06-19       Impact factor: 3.905

3.  Drug-protein hydrogen bonds govern the inhibition of the ATP hydrolysis of the multidrug transporter P-glycoprotein.

Authors:  Eduardo E Chufan; Khyati Kapoor; Suresh V Ambudkar
Journal:  Biochem Pharmacol       Date:  2015-12-11       Impact factor: 5.858

4.  Structures of the Multidrug Transporter P-glycoprotein Reveal Asymmetric ATP Binding and the Mechanism of Polyspecificity.

Authors:  Lothar Esser; Fei Zhou; Kristen M Pluchino; Joseph Shiloach; Jichun Ma; Wai-Kwan Tang; Camilo Gutierrez; Alex Zhang; Suneet Shukla; James P Madigan; Tongqing Zhou; Peter D Kwong; Suresh V Ambudkar; Michael M Gottesman; Di Xia
Journal:  J Biol Chem       Date:  2016-11-18       Impact factor: 5.157

5.  Global alteration of the drug-binding pocket of human P-glycoprotein (ABCB1) by substitution of fifteen conserved residues reveals a negative correlation between substrate size and transport efficiency.

Authors:  Shahrooz Vahedi; Eduardo E Chufan; Suresh V Ambudkar
Journal:  Biochem Pharmacol       Date:  2017-07-17       Impact factor: 5.858

6.  Human-Mouse Chimeras with Normal Expression and Function Reveal That Major Domain Swapping Is Tolerated by P-Glycoprotein (ABCB1).

Authors:  Kristen M Pluchino; Matthew D Hall; Janna K Moen; Eduardo E Chufan; Patricia A Fetsch; Suneet Shukla; Deborah R Gill; Stephen C Hyde; Di Xia; Suresh V Ambudkar; Michael M Gottesman
Journal:  Biochemistry       Date:  2016-02-10       Impact factor: 3.162

7.  Locking intracellular helices 2 and 3 together inactivates human P-glycoprotein.

Authors:  Tip W Loo; David M Clarke
Journal:  J Biol Chem       Date:  2013-11-25       Impact factor: 5.157

8.  The Transmission Interfaces Contribute Asymmetrically to the Assembly and Activity of Human P-glycoprotein.

Authors:  Tip W Loo; David M Clarke
Journal:  J Biol Chem       Date:  2015-05-18       Impact factor: 5.157

9.  Mutational Analysis of Intracellular Loops Identify Cross Talk with Nucleotide Binding Domains of Yeast ABC Transporter Cdr1p.

Authors:  Abdul Haseeb Shah; Manpreet Kaur Rawal; Sanjiveeni Dhamgaye; Sneha Sudha Komath; Ajay Kumar Saxena; Rajendra Prasad
Journal:  Sci Rep       Date:  2015-06-08       Impact factor: 4.379

10.  Theoretical insights on helix repacking as the origin of P-glycoprotein promiscuity.

Authors:  Cátia A Bonito; Ricardo J Ferreira; Maria-José U Ferreira; Jean-Pierre Gillet; M Natália D S Cordeiro; Daniel J V A Dos Santos
Journal:  Sci Rep       Date:  2020-06-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.